Harvest Integrated Research Organization (HiRO) is a CRO that serves both Asian biotechs looking to do clinical trials outside of the region, and US and European clients wanting to conduct clinical research in Asia. CEO and founder Karen Chu explains the company’s integrated approach and how it aims to maintain its “boutique” style while undergoing major expansion into Australia, New Zealand, the US, and South Korea. She also discusses the recent surge in clinical trials in the APAC region and the increasing quality of the data generated there.

A biotech sponsor based in China was conducting a clinical study on COVID-19 treatment in the United States and the Asia Pacific region, including China, in collaboration with a global contract research organization (CRO). 6 months into a new study start, facing site activation and patient recruitment challenges, biotech changes CRO and HiRO rescues Vaccine study.

Harvest Integrated Research Organization (HiRO), an innovation global CRO, is pleased to announce the successful acquisition of Courante Oncology, a US-based full-service clinical research provider specializing in oncology product development.

Harvest Integrated Research Organization (HiRO) is proud to announce that the highly regarded global pharmaceutical publication "Pharma Tech Outlook" named HiRO among the Top 10 CROs in Asia and the Pacific. 

HiRO announced the completion of its Series A financing in the tens of millions of US dollars. This round of investment is led by OrbiMed, with the participation from existing shareholder, Fontus Capital.

HiRO's acquisition of Pharmaceutical Solutions (PharmaSols or PSL), an agreement was formally signed in October 2021.

HiRO and CluePoints signed a partnership agreement to provide HiRO clients state-of-the-art Risk-Based Quality Management (RBQM) expertise and technical services in Greater China.